Acasti Pharma Q1 net loss $4.0M; FDA aligned on Phase 3 GTX-104 trial; cash runway to Q2 2025

Grace Therapeutics, Inc.

2023-Q1 EPS reported -$0.54

Net loss $4.0M ($0.54 per share) vs $4.5M ($0.61 per share) year ago.
Cash and equivalents $21.6M at quarter end; projected runway through Q2 2025 covering potential GTX-104 NDA submission.
FDA alignment on STRIVE-ON Phase 3 safety trial for GTX-104; first patient dosing expected Q4 2023.
R&D expenses fell to $1.1M from $2.3M on restructuring; $1.5M severance costs incurred.
Appointed new CMO, VP Clinical Operations, VP Program Management; expanded Scientific Advisory Board with three key opinion leaders.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Grace Therapeutics, Inc. reported fiscal quarter ended June 30, 2023 results: net income $4.0 million, EPS $0.54 per share.

Period: fiscal quarter ended June 30, 2023
Net income: $4.0 million
EPS: $0.54 per share
Result: reported results

Exact text from the filing

Acasti Pharma Inc. issued a press release announcing its financial results for the fiscal quarter ended June 30, 2023.

View on SEC.gov

309 earnings releases filed in the last 30 days. Browse all earnings releases →

Grace Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-041606

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.